09:18 AM EST, 01/17/2025 (MT Newswires) -- Novo Nordisk's ( NVO ) Ozempic, Wegovy and Rybelsus are among the 15 additional drugs selected for US Medicare price negotiations, the Department of Health and Human Services said Friday.

Novo Nordisk ( NVO ) shares were down 4.3% in premarket activity Friday.

The other drugs subject to the talks are:

GSK's (GSK) Trelegy Ellipta

Pfizer's ( PFE ) Xtandi and Ibrance

Bristol-Myers Squibb's ( BMY ) Pomalyst

Boehringer Ingelheim's Ofev

AbbVie's ( ABBV ) and Ironwood Pharmaceuticals' ( IRWD ) Linzess

AstraZeneca's ( AZN ) Calquence

Teva Pharmaceutical Industries' ( TEVA ) Austedo and Austedo XR

Theravance Biopharma's ( TBPH ) and GSK's Breo Ellipta

Boehringer Ingelheim's and Eli Lilly's ( LLY ) Tradjenta

Salix Pharmaceuticals' Xifaxan

AbbVie's ( ABBV ) Vraylar

Merck's ( MRK ) Janumet and Janumet XR

Amgen's ( AMGN ) Otezla